# US 12,005,045 B2 · Method of modulating TIGIT and PD-1 signalling pathways using 1,2,4-oxadiazole compounds > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 12,005,045 B2 - Document ID: US12005045B2 - Status: Granted - Kind: B2 - Application number: 18/518,292 - Filed: 2023-11-22 - Published: 2024-04-18 - Granted: 2024-06-11 - Earliest claimed: 2018-03-14 - Assignees: Aurigene Oncology Limited - Applicants: Aurigene Oncology Limited - Inventors: Pottayil Govindan Nair Sasikumar; Muralidhara Ramachandra; Seetharamaiah Setty Sudarshan Naremaddepalli; Chennakrishnareddy Gundala - Web page: https://patentgrep.com/patent/US12005045B2 ## CPC - A61K 31/4245: Oxadiazoles - A61P 35/00: Antineoplastic agents - C07D 271/06: 1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles - C07D 413/04: directly linked by a ring-member-to-ring-member bond - C07D 413/06: linked by a carbon chain containing only aliphatic carbon atoms - C07D 413/12: linked by a chain containing hetero atoms as chain links - Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08) - Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE ## Abstract The present invention relates to method of modulating TIGIT signaling pathway and PD-1 signaling pathway. The invention also encompasses the use of the compound of formula (I) or a stereoisomer thereof or a pharmaceutically acceptable salt thereof for the treatment of diseases or disorders mediated by both TIGIT signaling pathway and PD-1 signaling pathway. ## Claims ### Claim 1 A method of modulating T cell immunoreceptor with Ig and ITIM domains (TIGIT) signaling pathway and programmed cell death 1 (PD-1) signaling pathway in a subject in need thereof, comprising administering to the subject Compound 19: or a stereoisomer thereof or a pharmaceutically acceptable salt thereof. ### Claim 2 (depends on 1) The method of claim 1, wherein the subject in need thereof is suffering from a disease or disorder selected from a cancer, immune disorder, immunodeficiency disorder, inflammatory disorder, infectious disease, transplant rejection, or combination thereof. ### Claim 3 (depends on 2) The method of claim 2, wherein the disease or disorder is a cancer. ### Claim 4 (depends on 3) The method of claim 3, wherein the cancer is selected from blastoma, breast cancer, epithelial cancer, colon cancer, lung cancer, melanoma, prostate cancer, renal cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, uterine cancer, ovarian cancer, colorectal cancer, rectal cancer, cancer of the anal region, cancer of the peritoneum, stomach cancer, testicular cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, cervical cancer, vaginal cancer, vulval cancer, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma, cancer of the urethra, cancer of the penis, chronic or acute leukemia, solid tumors of childhood, Hodgkin's lymphoma, non-Hodgkin's lymphoma, cutaneous T cell lymphoma, mesothelioma, thymic carcinoma, myeloma, cancer of the bladder, cancer of the ureter, carcinoma of the renal pelvis, liver cancer, pancreatic cancer, post-transplant lymphoproliferative disorder (PTLD), neoplasm of the central nervous system (CNS), tumor angiogenesis, spinal axis tumor, brain stem glioma, pituitary adenoma, epidermoid cancer, salivary gland carcinoma, squamous cell cancer, abnormal vascular proliferation associated with phakomatoses, edema (such as that associated with brain tumors), Meigs' syndrome, Merkel cell carcinoma, and an environmentally induced cancer. ### Claim 5 (depends on 2) The method of claim 2, wherein the disease is an infectious disease. ### Claim 6 (depends on 5) The method of claim 5, wherein the infectious disease is a bacterial infection, a viral infection, a fungal infection, or a parasitic infection. ### Claim 7 A method of treating a disease or disorder mediated by both TIGIT signalling pathway and PD-1 signalling pathway in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of Compound 19: or a stereoisomer thereof or a pharmaceutically acceptable salt thereof. ### Claim 8 (depends on 7) The method of claim 7, wherein the disease or disorder is a cancer, immune disorder, immunodeficiency disorder, inflammatory disorder, infectious disease, transplant rejection, or combination thereof. ### Claim 9 (depends on 8) The method of claim 8, wherein the cancer is selected from blastoma, breast cancer, epithelial cancer, colon cancer, lung cancer, melanoma, prostate cancer, renal cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, uterine cancer, ovarian cancer, colorectal cancer, rectal cancer, cancer of the anal region, cancer of the peritoneum, stomach cancer, testicular cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, cervical cancer, vaginal cancer, vulval cancer, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma, cancer of the urethra, cancer of the penis, chronic or acute leukemia, solid tumors of childhood, Hodgkin's lymphoma, non-Hodgkin's lymphoma, cutaneous T cell lymphoma, mesothelioma, thymic carcinoma, myeloma, cancer of the bladder, cancer of the ureter, carcinoma of the renal pelvis, liver cancer, pancreatic cancer, post-transplant lymphoproliferative disorder (PTLD), neoplasm of the central nervous system (CNS), tumor angiogenesis, spinal axis tumor, brain stem glioma, pituitary adenoma, epidermoid cancer, salivary gland carcinoma, squamous cell cancer, abnormal vascular proliferation associated with phakomatoses, edema (such as that associated with brain tumors), Meigs' syndrome, Merkel cell carcinoma, and an environmentally induced cancer. ### Claim 10 (depends on 8) The method of claim 8, wherein the infectious disease is a bacterial infection, a viral infection, a fungal infection, or a parasitic infection. ### Claim 11 A method of modulating T cell immunoreceptor with Ig and ITIM domains (TIGIT) signaling pathway in a subject in need thereof, comprising administering to the subject Compound 19: or a stereoisomer thereof or a pharmaceutically acceptable salt thereof. ### Claim 12 (depends on 11) The method of claim 11, wherein the method further comprises modulating the PD-1 signalling pathway. ### Claim 13 (depends on 11) The method of claim 11, wherein the subject in need thereof is suffering from a disease or disorder selected from a cancer, immune disorder, immunodeficiency disorder, inflammatory disorder, infectious disease, transplant rejection, or combination thereof. ### Claim 14 (depends on 11) The method of claim 11, wherein the modulating is inhibiting growth of tumor cells and/or metastasis. ### Claim 15 (depends on 14) The method of claim 14, wherein the tumor cells are of a cancer selected from small cell lung cancer, multiple myeloma, bladder carcinoma, primary ductal carcinoma, ovarian carcinoma, Hodgkin's lymphoma, gastric carcinoma, acute myeloid leukemia, and pancreatic cancer. ### Claim 16 A method of treating a disease or disorder mediated by TIGIT signalling pathway in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of Compound 19: or a stereoisomer thereof or a pharmaceutically acceptable salt thereof. ### Claim 17 (depends on 16) The method of claim 16, wherein the disease or disorder is a cancer, immune disorder, immunodeficiency disorder, inflammatory disorder, infectious disease, transplant rejection, or combination thereof. ### Claim 18 (depends on 17) The method of claim 17, wherein the cancer is selected from blastoma, breast cancer, epithelial cancer, colon cancer, lung cancer, melanoma, prostate cancer, renal cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, uterine cancer, ovarian cancer, colorectal cancer, rectal cancer, cancer of the anal region, cancer of the peritoneum, stomach cancer, testicular cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, cervical cancer, vaginal cancer, vulval cancer, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma, cancer of the urethra, cancer of the penis, chronic or acute leukemia, solid tumors of childhood, Hodgkin's lymphoma, non-Hodgkin's lymphoma, cutaneous T cell lymphoma, mesothelioma, thymic carcinoma, myeloma, cancer of the bladder, cancer of the ureter, carcinoma of the renal pelvis, liver cancer, pancreatic cancer, post-transplant lymphoproliferative disorder (PTLD), neoplasm of the central nervous system (CNS), tumor angiogenesis, spinal axis tumor, brain stem glioma, pituitary adenoma, epidermoid cancer, salivary gland carcinoma, squamous cell cancer, abnormal vascular proliferation associated with phakomatoses, edema (such as that associated with brain tumors), Meigs' syndrome, Merkel cell carcinoma, and an environmentally induced cancer. ### Claim 19 (depends on 17) The method of claim 17, wherein the infectious disease is a bacterial infection, a viral infection, a fungal infection, or a parasitic infection.